Baricitinib - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for baricitinib and what is the scope of patent protection?
Baricitinib
is the generic ingredient in one branded drug marketed by Eli Lilly And Co and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.Baricitinib has one hundred and three patent family members in forty-four countries.
One supplier is listed for this compound.
Summary for baricitinib
International Patents: | 103 |
US Patents: | 6 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 117 |
Clinical Trials: | 118 |
Patent Applications: | 3,522 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for baricitinib |
What excipients (inactive ingredients) are in baricitinib? | baricitinib excipients list |
DailyMed Link: | baricitinib at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for baricitinib
Generic Entry Date for baricitinib*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for baricitinib
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Vanderbilt University Medical Center | Phase 2 |
University of Minnesota | Phase 2 |
Yale University | Phase 2 |
Pharmacology for baricitinib
Drug Class | Janus Kinase Inhibitor |
Mechanism of Action | Janus Kinase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for baricitinib
Paragraph IV (Patent) Challenges for BARICITINIB
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
OLUMIANT | Tablets | baricitinib | 4 mg | 207924 | 1 | 2023-10-03 |
OLUMIANT | Tablets | baricitinib | 1 mg and 2 mg | 207924 | 2 | 2022-05-31 |
US Patents and Regulatory Information for baricitinib
EU/EMA Drug Approvals for baricitinib
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Eli Lilly Nederland B.V. | Olumiant | baricitinib | EMEA/H/C/004085 Rheumatoid arthritisBaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Olumiant may be used as monotherapy or in combination with methotrexate.Atopic DermatitisOlumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy.Alopecia areataBaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5.1).Juvenile idiopathic arthritisBaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic DMARDs:- Polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular),- Enthesitis related arthritis, and- Juvenile psoriatic arthritis.Baricitinib may be used as monotherapy or in combination with methotrexate. |
Authorised | no | no | no | 2017-02-13 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for baricitinib
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 3459565 | PROCÉDÉS DE TRAITEMENT DE TROUBLES DE PERTE DE CHEVEUX (METHODS FOR TREATING HAIR LOSS DISORDERS) | ⤷ Try a Trial |
Israel | 208023 | אצטוניטרילים של {1-מותמר-3-[4-(h7-פירולו[3,2-d] פירימידינ-4-יל)-h1- פיראזול-1-יל]אזטידינ-3-יל} ותכשירים רוקחיים המכילים אותם (1-substituted-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azetidin-3-yl} acetonitriles and pharmaceutical compositions comprising them) | ⤷ Try a Trial |
Croatia | P20161390 | ⤷ Try a Trial | |
Ukraine | 101493 | ПРОИЗВОДНЫЕ АЗЕТИДИНА И ЦИКЛОБУТАНА КАК ИНГИБИТОРЫ JAK;ПОХІДНІ АЗЕТИДИНУ ТА ЦИКЛОБУТАНУ ЯК ІНГІБІТОРИ JAK (AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS) | ⤷ Try a Trial |
Dominican Republic | P2010000270 | DERIVADOS DE AZETIDINA Y CICLOBUTANO COMO INHIBIDORES DE JAK | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2012061537 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for baricitinib
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2288610 | CR 2017 00032 | Denmark | ⤷ Try a Trial | PRODUCT NAME: BARICITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1 /16/1170 20170215 |
2288610 | 2017C/025 | Belgium | ⤷ Try a Trial | PRODUCT NAME: OLUMIANT - BARICITINIB; AUTHORISATION NUMBER AND DATE: EU/1/16/1170 20170215 |
2288610 | 1790035-8 | Sweden | ⤷ Try a Trial | PRODUCT NAME: BARICITINIB; REG. NO/DATE: EU/1/16/1170 20170215 |
2288610 | LUC00027 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: BARICITINIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/16/1170 20170215 |
2288610 | SPC/GB17/045 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: BARICITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/16/1170/001(NI) 20170215; UK EU/1/16/1170/002(NI) 20170215; UK EU/1/16/1170/003(NI) 20170215; UK EU/1/16/1170/004(NI) 20170215; UK EU/1/16/1170/005(NI) 20170215; UK EU/1/16/1170/006(NI) 20170215; UK EU/1/16/1170/013(NI) 20170215; UK EU/1/16/1170/014(NI) 20170215; UK EU/1/16/1170/015(NI) 20170215; UK EU/1/16/1170/016(NI) 20170215; UK PLGB 14895/0255 20170215; UK PLGB 14895/0256 20170215; UK EU/1/16/1170/007(NI) 20170215; UK EU/1/16/1170/008(NI) 20170215; UK EU/1/16/1170/009(NI) 20170215; UK EU/1/16/1170/010(NI) 20170215; UK EU/1/16/1170/011(NI) 20170215; UK EU/1/16/1170/012(NI) 20170215 |
2288610 | 33/2017 | Austria | ⤷ Try a Trial | PRODUCT NAME: BARICITINIB UND PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/16/1170 (MITTEILUNG) 20170215 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.